Please login to the form below

Not currently logged in
Email:
Password:

Daichii Sankyo

This page shows the latest Daichii Sankyo news and features for those working in and with pharma, biotech and healthcare.

Astellas, Daiichi Sankyo and Takeda to study biomarkers

Astellas, Daiichi Sankyo and Takeda to study biomarkers

Collaboration aims to establish comprehensive database to accelerate drug development.  . Japanese pharmaceutical firms Astellas, Daiichi Sankyo and Takeda have joined forces to create a comprehensive database of biomarkers from healthy adults.

Latest news

  • AZ and Daiichi Sankyo sign Movantik marketing deal AZ and Daiichi Sankyo sign Movantik marketing deal

    AstraZeneca has announced a new co-commercialisation agreement with Daiichi Sankyo for the constipation drug Movantik (naloxegol) in the US.  . ... AstraZeneca will be responsible for all manufacturing, will book all sales and will make sales-related

  • Thin on the ground

    Daichii Sankyo is developing edoxaban tosylate, which is also an orally active direct factor Xa inhibitor.

  • News in brief, June 20, 2007

    Its clients include US and EU pharmaceutical and biotechnology corporations including Allergan, Biogen Idec, Bristol-Myers Squibb, sanofi-aventis and Daichii Sankyo.

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics